Share-based Payment Arrangement, Expense of Oric Pharmaceuticals, Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Oric Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Oric Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $5,631,000, a 11% increase year-over-year.
  • Oric Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $23,962,000, a 27% increase year-over-year.
  • Oric Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $20,213,000, a 33% increase from 2023.
  • Oric Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $15,226,000, a 5.3% increase from 2022.
  • Oric Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $14,460,000, a 13% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Oric Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $23,962,000 $5,631,000 +$575,000 +11% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $23,387,000 $6,574,000 +$1,578,000 +32% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $21,809,000 $6,554,000 +$1,596,000 +32% 01 Jan 2025 31 Mar 2025 10-Q 05 May 2025 2025 Q1
Q4 2024 $20,213,000 $5,203,000 +$1,280,000 +33% 01 Oct 2024 31 Dec 2024 10-K 18 Feb 2025 2024 FY
Q3 2024 $18,933,000 $5,056,000 +$1,192,000 +31% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $17,741,000 $4,996,000 +$1,171,000 +31% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $16,570,000 $4,958,000 +$1,344,000 +37% 01 Jan 2024 31 Mar 2024 10-Q 05 May 2025 2025 Q1
Q4 2023 $15,226,000 $3,923,000 +$793,000 +25% 01 Oct 2023 31 Dec 2023 10-K 18 Feb 2025 2024 FY
Q3 2023 $14,433,000 $3,864,000 +$571,000 +17% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $13,862,000 $3,825,000 -$267,000 -6.5% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $14,129,000 $3,614,000 -$331,000 -8.4% 01 Jan 2023 31 Mar 2023 10-Q 06 May 2024 2024 Q1
Q4 2022 $14,460,000 $3,130,000 -$369,000 -11% 01 Oct 2022 31 Dec 2022 10-K 11 Mar 2024 2023 FY
Q3 2022 $14,829,000 $3,293,000 -$104,000 -3.1% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $14,933,000 $4,092,000 +$879,000 +27% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $14,054,000 $3,945,000 +$1,201,000 +44% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $12,853,000 $3,499,000 +$1,810,000 +107% 01 Oct 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $11,043,000 $3,397,000 +$1,716,000 +102% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $9,327,000 $3,213,000 +$1,832,000 +133% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $7,495,000 $2,744,000 +$2,217,000 +421% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $5,278,000 $1,689,000 +$1,256,000 +290% 01 Oct 2020 31 Dec 2020 10-K 21 Mar 2022 2021 FY
Q3 2020 $4,022,000 $1,681,000 +$1,410,000 +520% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $2,612,000 $1,381,000 +$1,191,000 +627% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $1,421,000 $527,000 +$327,000 +164% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $1,094,000 $433,000 01 Oct 2019 31 Dec 2019 10-K 21 Mar 2022 2021 FY
Q3 2019 $271,000 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $190,000 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $200,000 01 Jan 2019 31 Mar 2019 10-Q 20 May 2020 2020 Q1

Oric Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $20,213,000 +$4,987,000 +33% 01 Jan 2024 31 Dec 2024 10-K 18 Feb 2025 2024 FY
2023 $15,226,000 +$766,000 +5.3% 01 Jan 2023 31 Dec 2023 10-K 18 Feb 2025 2024 FY
2022 $14,460,000 +$1,607,000 +13% 01 Jan 2022 31 Dec 2022 10-K 11 Mar 2024 2023 FY
2021 $12,853,000 +$7,575,000 +144% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $5,278,000 +$4,184,000 +382% 01 Jan 2020 31 Dec 2020 10-K 21 Mar 2022 2021 FY
2019 $1,094,000 +$625,000 +133% 01 Jan 2019 31 Dec 2019 10-K 21 Mar 2022 2021 FY
2018 $469,000 01 Jan 2018 31 Dec 2018 10-K 23 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.